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Expression and regulation of the NALP3 inflammasome
complex in periodontal diseases
Abstract
Periodontitis is an infectious process characterized by inflammation affecting the supporting structures
of the teeth. Porphyromonas gingivalis is a major oral bacterial species implicated in the pathogenesis of
periodontitis. Processing of interleukin (IL)-1 family cytokines is regulated by an intracellular innate
immune response system, known as the NALP3 [nacht domain-, leucine-rich repeat-, and pyrin domain
(PYD)-containing protein 3] inflammasome complex. The aim of the present study was to investigate by
quantitative real-time polymerase chain reaction (PCR) the mRNA expression of NALP3, its effector
molecule apoptosis associated speck-like protein (ASC), its putative antagonist NLRP2 (NLR family,
PYD-containing protein 2), IL-1beta and IL-18 (i) in gingival tissues from patients with gingivitis (n =
10), chronic periodontitis (n = 18), generalized aggressive periodontitis (n = 20), as well as in healthy
subjects (n = 20), (ii) in vitro in a human monocytic cell line (Mono-Mac-6), in response to P. gingivalis
challenge for 6 h. The clinical data indicate that NALP3 and NLRP2, but not ASC, are expressed at
significantly higher levels in the three forms of inflammatory periodontal disease compared to health.
Furthermore, a positive correlation was revealed between NALP3 and IL-1beta or IL-18 expression
levels in these tissues. The in vitro data demonstrate that P. gingivalis deregulates the NALP3
inflammasome complex in Mono-Mac-6 cells by enhancing NALP3 and down-regulating NLRP2 and
ASC expression. In conclusion, this study reveals a role for the NALP3 inflammasome complex in
inflammatory periodontal disease, and provides a mechanistic insight to the host immune responses
involved in the pathogenesis of the disease by demonstrating the modulation of this cytokine-signalling
pathway by bacterial challenge.
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Abstract 
Periodontitis is an infectious process characterized by inflammation affecting the 
supporting structures of the teeth. Porphyromonas gingivalis is a major oral bacterial 
species implicated in the pathogenesis of periodontitis. Processing of Interleukin-1 
family cytokines is regulated by an intracellular innate immune response system, 
known as the NALP3 Inflammasome complex. The aim of the present study was to 
investigate by quantitative real-time PCR the mRNA expression of NALP3, its 
effector molecule ASC, its putative antagonist NLRP2, IL-1β and IL-18, a) in 
gingival tissues from patients with gingivitis (n=10), chronic periodontitis (n=18), 
generalised aggressive periodontitis (n=20), as well as healthy subjects (n=20), b) in 
vitro in a human monocytic cell line (Mono-Mac-6), in response to P. gingivalis 
challenge for 6 h. The clinical data indicate that NALP3 and NLRP2, but not ASC, 
are expressed at significantly higher levels in the three forms of inflammatory 
periodontal disease compared to health. Furthermore, a positive correlation was 
revealed between NALP3 and IL-1β or IL-18 expression levels in these tissues. The 
in vitro data demonstrates that P. gingivalis deregulates the NALP3 Inflammasome 
complex in Mono-Mac-6 cells, by enhancing NALP3 and down-regulating NLRP2 
and ASC expression. In conclusion, this study reveals a role for the NALP3 
Inflammasome complex in inflammatory periodontal disease, and provides a 
mechanistic insight to the host immune responses involved in the pathogenesis of the 
disease by demonstrating the modulation of this cytokine-signaling pathway by 
bacterial challenge. 
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Introduction 
Periodontal disease is defined as any condition affecting the periodontium [1], which 
is the consortium of tissues surrounding and supporting the tooth, including the 
gingiva and alveolar bone. The most common are those caused by the accumulation of 
a bacterial biofilm on the tooth surface, triggering inflammation and subsequent 
destruction of the periodontium. The inflammatory processes involve the activation of 
the broad axis of innate immunity, specifically by up-regulation of proinflammatory 
cytokines [2-5]. Pro-inflammatory cytokines including members of the Interleukin 
(IL)-1 family, such as IL-1β and IL-18, are present in the diseased periodontium and 
their unbalanced production appears to mediate periodontal tissue destruction [6-9]. 
Porphyromonas gingivalis is a Gram-negative bacterial species, which constitutes a 
major component of the pathogenic microbiota implicated in chronic periodontitis, 
[10-13]. This is a form of periodontal disease characterised by the progressive 
destruction of the alveolar bone, eventually leading to tooth loss. 
Recent evidence demonstrates that the downstream processing of IL-1β is 
regulated by a cytosolic protein complex of the nucleotide-binding oligomerization 
domain-like receptor (NLR) protein family, namely NALP3 / Cryopyrin-
Inflammasome [14, 15]. This is essentially a family of intracellular innate immune 
sensors that can respond to bacterial challenge, initiating early host responses [16]. 
The inflammasome cooperates with the Toll-like receptor (TLR) pathways to mediate 
a rapid response to pathogens [17, 18]. NALP3 (also known as PYPAF-1, NLRP3 or 
Cryopyrin) exerts its inflammatory effects through apoptosis associated speck-like 
protein (ASC) that functions as an adaptor to downstream pathways [19]. Co-
expression of NALP3 and ASC activate Caspase-1, which in turn leads to cleavage 
and activation of IL-1β [20]. Moreover, NLRP2 (PYPAF-2, or Pyrin), a protein 
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related to the NALP3 inflammasome, was shown to inhibit NALP3-ASC interactions 
[21]. Recent studies revealed an essential role for NALP3 inflammasome in mediating 
IL-1β production in response to several bacterial ligands including LPS, 
peptidoglycan, bacterial and viral RNA [22-26]. Peripheral blood mononuclear cells 
(PBMCs), particularly monocytes, which are known to be high producers of IL-1β, 
are reported to express NALP3 mRNA [27, 28], and this was highly induced by 
bacterial lipopolysaccharide (LPS) [29]. Moreover, NALP3-deficient macrophages do 
not produce IL-1β in response to bacterial stimulation [23, 24, 30, 31]. Interestingly, 
monocytes from patients with a mutation within the nucleotide-binding 
oligomerization domain of the NALP3 gene, exhibit spontaneous activation of IL-1β 
production that can be further potentiated by LPS [32]. Notably, treatment of these 
patients with an IL-1 receptor antagonist reverses the clinical symptoms, suggesting a 
cause-effect relationship between IL-1β production and the development of disease 
[33]. 
The fundamental involvement of inflammasome complexes in inflammatory 
responses is been emphasized by the fact that  mutations in the NALP3 gene are 
strongly associated with auto-inflammatory conditions, such as rheumatoid arthritis, 
Muckle-Wells syndrome, Crohn’s disease, familial cold auto-inflammatory syndrome, 
but also septic shock [34-39]. Hyper-production of IL-1β is considered to be a central 
event in the pathogenesis of auto-inflammatory conditions [40]. 
The potential involvement of NALP3 in the pathogenesis of more common 
inflammatory disorders prompted us to investigate its role in periodontal diseases 
[26]. While it is known that the NALP3 inflammasome is expressed in monocytic 
cells, the regulation of this by periodontal pathogens has yet to be revealed. We 
hypothesized that the inflammasome complex would be altered in patients with 
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periodontal disease, and that its expression would be regulated in monocytic cells 
challenged by periodontal pathogens. Therefore, the aim of this study was to 
investigate the gene expression of NALP3, NLRP2, ASC, IL-18 and IL-1β in clinical 
samples of gingival tissues from patients with various forms of periodontal disease 
and healthy subjects. The further aim was to investigate in vitro the regulation of this 
complex by P. gingivalis in a human monocytic cell line, namely Mono-Mac-6. 
 
Materials and Methods 
 
Study population and clinical examination 
A total of 58 subjects were included in this study, recruited from the Department of 
Periodontology, School of Dentistry, Ege University, İzmir. The use of human 
subjects satisfied the requirements of Ege University Faculty of Medicine Institutional 
Review Board and was conducted in accordance with the Helsinki Declaration. 
Written and informed consent was obtained from each subject prior to enrolment in 
the study. The selection of the patients was made according to the clinical and 
radiographic criteria proposed by the 1999 International World Workshop for a 
Classification of Periodontal Disease and Conditions [41]. Complete medical and 
dental histories were taken from all subjects. None of the subjects had history of 
systemic disease, or cigarette smoking, and had not taken medications such as 
antibiotics or contraceptives that could affect their periodontal status for at least 3 
months prior to the study. Clinical periodontal examination included measurement of 
probing pocket depth, clinical attachment level at six sites around each tooth with a 
manual probe, full-mouth papilla bleeding index and plaque index. The healthy group 
consisted of 3 females and 7 males (from 16 to 36 years, mean age 24.2 ± 8.4 years) 
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with no clinical signs of gingival inflammation or radiographic evidence of alveolar 
bone loss, and mean probing pocket depth 1.75 ± 0.63 mm, plaque index 0.8 ± 0.9, 
and papilla bleeding index 0.3 ± 0.4. The gingival tissue samples were taken from 
non-bleeding sites. The gingivitis group included 4 female and 6 male patients (from 
22 to 48 years, mean age 34.2 ± 8.7 years), which exhibited varying degrees of 
gingival inflammation, no radiographic evidence of alveolar bone loss, mean probing 
pocket depth 2.7 ± 0.6 mm, plaque index 2.2 ± 1.3, and papilla bleeding index 2.6 ± 
0.84. The generalized aggressive periodontitis (G-AgP) group consisted of 12 females 
and 8 males (from 21 to 38 years, mean age 28.3 ± 4.6 years), with mean probing 
pocket depth 7.0 ± 1.2 mm, clinical attachment loss 7.4 ± 1.6 mm, plaque index 2.3 ± 
0.8, and papilla bleeding index 2.7 ± 1.4. The chronic periodontitis (CP) group 
included 8 females and 10 males (from 35 to 61 years, mean age of 46.6 ± 6.2 years), 
with mean probing pocket depth 6.6 ± 0.84 mm, clinical attachment loss 7.8 ± 1.7 
mm, plaque index 2.3 ± 0.77, and papilla bleeding index 3.1 ± 1.78. 
 
Collection of gingival tissue samples  
Gingival tissue samples, including both epithelium and connective tissue, were taken 
from the approximal sites of single rooted teeth prior to non-surgical periodontal 
therapy in the instance of periodontally diseased subjects, and during tooth extractions 
for orthodontic reasons, or crown lengthening procedures in healthy subjects. One 
tissue sample from each subject was obtained and immediately submerged in a sterile 
tube containing RNAlater solution (Ambion Inc, Austin, TX, USA), stored at -40°C 
until further laboratory analysis. 
 
 
 7
 
RNA isolation and Reverse Transcription 
Total RNA from gingival tissue biopsies was extracted using the RiboPure RNA 
Isolation Kit (Ambion Inc, Austin, TX, USA), according to the manufacturer’s 
instructions. The extracted total RNA concentration was quantified using NanoDrop® 
ND-1000 spectrophotometer (NanoDrop Technologies, USA). One µg of total RNA 
was incubated with 0.5 µg/ml of oligo dT primer (Promega, Southampton, UK) at 
70°C for 5 min and cooled on ice. A master mix was then added to the samples, 
comprising of 10 mM dNTPs, 200 units of moloney murine leukemia virus (M-MLV) 
reverse-transcriptase and buffer (Promega, Southampton, UK).  For the reverse-
transcription reaction, these samples were incubated at 40°C for 60 min, 70°C for 15 
min, and then cooled down to 4°C. The resulting cDNA was stored at -20°C, until 
further use. 
 
Quantitative real-time PCR (qPCR) analysis 
To quantify the mRNA expression levels, qPCR was performed on the prepared 
cDNA samples. TaqMan® Gene Expression Assays (Applied Biosystems, UK) and 
ROX qPCR mastermix were used for the amplification reactions, and the qPCR 
analyses were performed in an ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems, UK). The expressions of following target genes (Assay ID) 
were investigated: NALP3 (Hs00918085-m1), ASC (Hs01547324-m1), NLRP2 
(Hs01546938-m1), IL-18 (Hs01038787-ml), and IL1β (Hs00174097-m1). The 
housekeeping genes used to normalise the target gene Ct values in the clinical 
samples were GAPDH (Hs99999905-m1) and 18S rRNA (Hs99999901-s1), while the 
ones used for the in vitro experiments were ubiquitin C (UBC) (Hs01871556-m1) and 
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GAPDH. The amplification conditions were 10 min at 95 °C, followed by 40 cycles at 
95 °C for 15 sec, and 60 °C for 1 min. Each qPCR run also included non-template 
controls, which generated a Ct greater than 40 in all experiments. The expression 
levels were calculated by using the comparative Ct method (2−∆Ct formula) after 
normalization against the selected housekeeping genes. 
 
Bacterial culture 
Porphyromonas gingivalis wild-type W50 strain was grown on blood agar plates 
supplemented with 5% horse blood in an anaerobic environment containing 80% 
nitrogen, 10% hydrogen and 10% CO2 at 37°C, then was sub-cultured into 10 ml of 
media consisting of brain heart infusion broth supplemented with 5 µg/ml of hemin. 
The following day, the 10 ml culture was inoculated into 90 ml of fresh media. At day 
6, the liquid cultures were centrifuged at 8500 rpm for 45 min at 4ºC. The resulting 
culture supernatant was collected, aliquoted and stored at -80°C, to be used for further 
experimentation. Total bacterial protein concentration in 6-day culture supernatants of 
P. gingivalis strain W50 was determined using the Bio-Rad Protein Assay (Bio-Rad, 
Hertfordshire, UK). 
 
Cell culture 
The human myelomonocytic cell line Mono-Mac-6 was obtained from the German 
Collection of Microorganisms and Cell Cultures (Mascheroder, Braunschweig, 
Germany). Mono-Mac-6 cells were cultured in RPMI-Glutamax, supplemented with 
10% fetal bovine serum, 1% non-essential amino acids, 1% sodium pyruvate (all from 
Gibco BRL Life Technologies, UK) and 9 µg/ml bovine insulin (Sigma-Aldrich, UK). 
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The cells were confirmed to be free of mycoplasma infection prior to experimentation 
(MycoAlert® Mycoplasma Detection Assay, Lonza, Switzerland). Mono-Mac-6 cells 
(1 x 106/ml) were used for induction assays in a total volume of 200 µl per well in the 
absence or presence of P. gingivalis. The doses used were based on results from 
previous studies [42]. Each experiment was carried out in triplicate cultures.  
 
 
Statistical analysis 
For the clinical data, non-parametrical statistical analysis was employed. Comparisons 
between the groups were performed using the Kruskal –Wallis test, with Dunn’s 
multiple comparison test. Spearman’s rank correlation analysis was used to 
investigate the possible correlations between NALP3 and IL-1β, or IL-18 expression 
levels. For the in vitro experimental data, the statistical significances were analysed 
by a one-way analysis of variance (ANOVA), with Bonferroni post-hoc test. P<0.05 
values were considered to be statistically significant. All data analysis was performed 
with GraphPad Prism Software Version 4.0. 
 
RESULTS 
 
 
NALP3, ASC, NLRP2, IL-1β and IL-18 mRNA expression analysis in gingival 
tissues by qPCR 
The expressions of NALP3, its effector protein ASC, and its putative antagonist 
NLRP2 were examined in gingival tissues from patients with gingivitis, CP, G-AgP, 
as well as healthy subjects. All three gene products were readily measurable by qPCR 
in all tissues. In comparison to healthy tissues, NALP3 expression was significantly 
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(P<0.05) higher in either of the periodontitis groups or gingivitis groups (Fig. 1a). In 
particular, NALP3 expression was higher by 7.4-fold in G-AgP, 4.3-fold in CP, and 
7.7-fold in gingivitis, respectively. Interestingly, when the three disease groups were 
compared to each other, no significant differences were observed in the expression of 
these genes. Likewise, NLRP2 expression was increased in all disease groups 
compared to healthy tissues (Fig. 1a), but this was statistically significant (P<0.05) 
only in G-AgP (6-fold) and gingivitis (8.2-fold). In contrast, there were no significant 
differences in ASC expression between any of the disease groups and health (Fig. 1c). 
In comparison to healthy tissues, both IL-1β and IL-18 mRNA expressions were 
significantly (P<0.05) higher in gingivitis, CP and G-AgP. In the case of IL-1β 
mRNA expression, this was higher by 7.1-fold in G-AgP, 8.2-fold in CP, and 5.8-fold 
in gingivitis, respectively. When the disease groups were compared to each other, 
there were no significant differences between them in either IL-1β or IL-18 mRNA 
expression. 
Since NALP3 is involved in IL-1β and IL-18 activation, its possible 
correlation with IL-1β and IL-18 mRNA levels in the gingival tissues was 
investigated (Fig. 2). Spearman's rank correlation analysis indicated that the 
expression levels of NALP3 were positively correlated with IL-1β and IL-18 (r = 
0.62, P<0.0001, and r = 0.45, P<0.0004, respectively). 
 
Regulation of NALP3, ASC, NLRP2, IL-1β and IL-18 mRNA expression by P. 
gingivalis in monocytic cells 
The regulation of the inflammasome complex by P. gingivalis was also studied in 
vitro. Mono-Mac-6 cells were challenged with ascending protein concentrations of P. 
gingivalis W50 strain culture supernatants, for 6 h. The untreated (control) cell 
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cultures expressed low but detectable levels of NALP3 mRNA. Nevertheless, P. 
gingivalis challenge elicited a dose-dependent increase in NALP3 mRNA expression, 
which was up to 3-fold greater to the control (Fig 3a).  In contrast, NLRP2 mRNA 
expression was highly expressed in the untreated cells, and this was down-regulated 
in a dose-dependent manner by P. gingivalis challenge (Fig. 3b). Compared to the 
control, there was 9.3-fold reduction in NLRP2 expression levels with the highest P. 
gingivalis protein concentration used (6.4 µg/ml). Furthermore, ASC was highly 
expressed in the untreated control, but this was down-regulated up to 15.3-fold with 
increasing P. gingivalis concentrations (Fig. 3c). During this period, the expressions 
of IL-1β (Fig. 3d) and IL-18 (Fig. 3e) were enhanced in response to P. gingivalis 
challenge.  
 
Discussion 
The NALP3 Inflammasome complex is predicted to be an essential part of the innate 
immunity system [43]. The present study is the first to investigate the involvement of 
this complex in periodontal diseases, demonstrating significantly increased levels of 
NALP3 and NLRP2, but not ASC, mRNA expression in gingival tissues affected by 
periodontal disease, compared to health ones. Nevertheless, the impact of age 
differences between groups as a confounder should not be excluded, especially since 
this factor may alter immune responses, including the expression of this system. As 
expected, both IL-1β and IL-18 mRNA expression were also enhanced in periodontal 
disease compared to health, in consistency with previous findings [8, 9, 44]. 
Therefore, we further considered a potential relationship between these two cytokines 
of the IL-1 family and NALP3, and hypothesized a putative correlation at the tissue 
gene expression level. Indeed, a positive correlation was revealed, denoting functional 
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relationship of NALP3 with its downstream processing targets IL-1β and IL-18, in 
periodontal diseases. It is of interest that, while IL-1 cytokines and NALP3 
Inflammasome gene expression were significantly higher in gingivitis, CP and G-AgP 
compared to health, there were no differences among these three disease groups. This 
indicates that the enhancement of the inflammasome complex expression is 
distinguishable in the presence of inflammatory periodontal disease. However, it 
cannot differentiate between periodontitis and gingivitis, and therefore it may not 
account for the alveolar bone destruction, which occurs in the case of periodontitis, 
but not gingivitis. We have previously demonstrated that the receptor activator of NF-
κB Ligand (RANKL)-osteoprotegerin (OPG) system may be a more suitable indicator 
of bone destruction, rather than an inflammatory determinant of periodontal disease 
[45, 46]. 
These clinical data indicate high NALP3 Inflammasome expression levels in 
diseased gingival tissues. The inflamed gingival periodontal tissues are characterized 
by an influx of inflammatory cells, including neutrophils and monocytes/ 
macrophages [47]. These cells have been shown to express the NALP3 
Inflammasome complex, sensing and responding to bacterial challenge [29, 48]. We 
employed the Mono-Mac-6 cell line and selected P. gingivalis, a major periodontal 
pathogen, as bacterial challenge to investigate the regulation of the NALP3 
Inflammasome complex. NALP3 expression was low in untreated cells, but this was 
significantly elevated upon P. gingivalis challenge, along with the expressions of IL-
1β and IL-18. In agreement with these findings, we have previously shown that P. 
gingivalis triggers the release of IL-1β and IL-18, the endpoint targets of 
inflammasome activation, in Mono-Mac-6 cells [42]. Whether NALP3 is directly 
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involved in the induction these cytokines in the present experimental system, needs to 
be addressed by interventional studies. 
The present study also shows that Mono-Mac-6 cells constitutively express 
ASC, an important adapter molecule in NALP3-mediated cellular responses [29, 49, 
50]. Interestingly, P. gingivalis challenge dramatically down-regulated ASC mRNA 
expression, providing evidence of the functionality of this molecule in the regulation 
of the NALP3 in human monocytes [51]. These findings are in agreement with a 
recent report showing a decrease of ASC mRNA expression in differentiated THP-1, 
after 6 h of challenge with live P. gingivalis [52]. In contrast, another study has 
demonstrated that E. coli LPS enhances ASC mRNA expression in monocytic cells 
[53]. This discrepancy could reflect differences in the cell lines used, or the simply the 
different nature of bacterial stimulation. In fact, P. gingivalis has the capacity to evade 
immune responses, and thus contribute to the establishment of chronic inflammation 
[54]. Down-regulation of ASC may be a host response potentially manipulated by P. 
gingivalis, in favour of its survival in the infected periodontal tissues, as also 
discussed by other researchers [52]. 
Mono-Mac-6 cells constitutively expressed NLRP2 mRNA, and its levels 
were reduced after P. gingivalis challenge. NLRP2 was shown to compete with 
Caspase-1 for binding to ASC [21], and has also been proposed as an antagonist of 
NALP3-ASC interactions [55], thereby exerting a modulatory effect on IL-1β 
production. Thus, NLRP2 might interfere with NALP3-mediated cytokine production 
at several points in the signalling cascade [56]. The present demonstration of NLRP2 
down-regulation by P. gingivalis may denote that this molecule is part of a negative 
regulatory loop of the NALP3 Inflammasome complex.  
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In conclusion, the present study demonstrated an enhanced expression of the 
NALP3 Inflammasome complex in inflammatory periodontal diseases, occurring both 
in gingivitis and periodontitis. This cytokine-signaling pathway may therefore be 
crucial in the regulatory control of inflammatory responses in periodontal diseases. 
The findings are further potentiated by a mechanistic insight revealing a cross-talk 
between P. gingivalis and the NALP3 Inflammasome complex in human monocytic 
cells. P. gingivalis is likely to affect this complex by differentially regulating its 
individual components. The up-regulation of NALP3 and down-regulation of its 
inhibitor NLRP2 denote a positive regulatory effect on IL-1 cytokines. Nevertheless, 
since ASC promotes the processing of latent into mature IL-1β [18, 30], its down-
regulation by P. gingivalis suggests that it may attempt to dampen down the 
production of this cytokine. It is therefore tempting to postulate a pathway by which 
P. gingivalis may manipulate the host inflammatory responses, in order to survive and 
prevail within the infected periodontal tissues. 
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Figure Legends 
 
Figure 1 
The NALP3 Inflammasome complex expression levels in periodontal diseases. 
Distribution of NALP3 (a), NLRP2 (b), ASC (c), IL-1β (d) and IL-18 (e) gene 
expression in gingival tissues of healthy subjects (n=10), and patients with gingivitis 
(n=10), CP (n=18) and G-AgP (n=20). The mRNA expression levels were measured 
by qPCR analysis, normalized against the expression levels of GAPDH and 18S 
RNA. 
 
Figure 2 
Scatter plot showing the correlation between the NALP3 and IL-1β (a) or IL-18 (b) 
mRNA expression in gingival tissues from all subjects (n=58).  
 
Figure 3 
Regulation of the NALP3 Inflammasome complex expression by P. gingivalis. Mono-
Mac-6 cell cultures were challenged with ascending protein concentrations of P. 
gingivalis culture supernatant, for 6 h. The mRNA expression levels of NALP-3 (a), 
NLRP2 (b), ASC (c), IL-1β (d) and IL-18 (e), were measured by qPCR analysis, and 
normalized against the expression levels of GAPDH and UBC. Bars represent mean 
values ± SEM from three independent experiments. The asterisk indicates the groups 
that were significantly different to the control group (P<0.05). 
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